河南羚锐制药股份有限公司关于大股东部分股份质押的公告

Core Viewpoint - The announcement details the pledge of shares by the major shareholder, Lingrui Group, which holds a significant portion of Lingrui Pharmaceutical's stock, indicating a controlled risk situation without adverse effects on the company's operations or governance [2][3]. Group 1: Share Pledge Details - Lingrui Group holds 121,817,898 shares of Lingrui Pharmaceutical, accounting for 21.48% of the total share capital. After pledging 4,800,000 shares, the total pledged shares amount to 31,730,000, representing 26.05% of Lingrui Group's holdings and 5.59% of the company's total share capital [2]. - As of the announcement date, the total pledged shares by Lingrui Group and its concerted parties stand at 31,730,000, which is 5.59% of the company's total share capital [2]. Group 2: Impact Assessment - The share pledge by Lingrui Group is not expected to negatively impact the company's main business, financing credit, financing costs, or ongoing operational capabilities [3]. - The risk associated with the pledge is deemed controllable, and it will not lead to changes in the actual control of the company or adversely affect its production, governance, or independence [3]. - The company will continue to monitor the share pledge situation of its major shareholders and comply with relevant regulations for timely information disclosure [3].